Robert L. Ferris, MD, PhD, highlights groundbreaking advancements presented at the recent World Congress on Lung Cancer held ...
Cyrus M. Khan, MD, highlights some of the most recent and significant advancements in chronic lymphocytic leukemia treatment.
Yousef Zakharia, MD, discussed some of the available combination therapies for non–clear Cell renal cell carcinoma treatment.
During a Case-Based Roundtable® event, Ticiana Leal, MD, discusses phase 3 trials of combinations in the non–small cell lung ...
Sergio A. Giralt, MD, discusses what the most commonly used conditioning regimens for patients with myelodysplastic syndrome undergoing transplants are.
The FDA was expected to decide on the application of sotorasib and panitumumab for the treatment of metastatic colorectal ...
The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is ...
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the safety data from the phase 3 CEPHEUS trial in newly diagnosed multiple myeloma.
The FREEDOM2 study demonstrates that fedratinib is an effective second-line treatment for myelofibrosis after ruxolitinib ...
During a Case-Based Roundtable® event, Ursa Brown-Glaberman, MD, discussed options for the treatment of patients with ...
Elizabeth A. Brem, MD, discusses the shift she has seen in the community setting when it comes to using bispecific antibody ...
Aniket Bankar, MD, discusses why rusfertide is considered a promising therapeutic approach for patients with polycythemia vera.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results